Precision BioSciences Inc DTIL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Trading Information
- Previous Close Price
- $8.12
- Day Range
- $8.40–11.29
- 52-Week Range
- $3.53–11.29
- Bid/Ask
- $9.90 / $10.10
- Shares Outstanding
- 27.94M
- Market Cap
- $275.73M
- Volume/Avg
- 1,226 / 293,803
Key Statistics
- Price/Earnings (Normalized)
- 22.19
- Price/Sales
- 5.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 69
Valuation
Metric | DTIL |
|---|---|
Price/Earnings (Normalized) | 22.19 |
Price/Book Value | 5.32 |
Price/Sales | 5.32 |
Price/Cash Flow | — |
Price/Earnings
DTIL
Financial Strength
Metric | DTIL |
|---|---|
Quick Ratio | 9.90 |
Current Ratio | 10.47 |
Interest Coverage | −32.99 |
Quick Ratio
DTIL
Profitability
Metric | DTIL |
|---|---|
Return on Assets (Normalized) | −27.19% |
Return on Equity (Normalized) | −61.52% |
Return on Invested Capital (Normalized) | −46.78% |
Return on Assets
DTIL
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|&S^TsH | LOCK|#f#h | $138B | |||
| Moderna Inc MRNA | LOCK|R^Q^@? | LOCK|ZQ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%@&N>Y | LOCK|$Z#p | $93B | |||
| argenx SE ADR ARGX | LOCK|^!T<<^K | LOCK|SX! | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#qBMBn | LOCK|Glm | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|P<z%?$d | LOCK|@@&K | $30B | |||
| Incyte Corp INCY | LOCK|B@^MCF | LOCK|X<x | $24B | |||
| BioNTech SE ADR BNTX | LOCK|%<MJjC# | LOCK|rgn | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|x#WdL^ | LOCK|<T?N | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|kn^&b^! | LOCK|M^ | $15B |
United States